LRRC8A and familial pancreatic carcinoma: For pancreatic cancer, LRRC8A inhibition presents the intriguing possibility of converting an immunosuppressive microenvironment to an immunopermissive one, potentially synergizing with checkpoint inhibitor immunotherapies.